<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002008</url>
  </required_header>
  <id_info>
    <org_study_id>067D</org_study_id>
    <secondary_id>106</secondary_id>
    <nct_id>NCT00002008</nct_id>
  </id_info>
  <brief_title>An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia</brief_title>
  <official_title>An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the safety, immunogenicity, biological activity, ad pharmacokinetics of&#xD;
      sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) human&#xD;
      granulocyte-macrophage colony-stimulating factor ( GM-CSF ), given by subcutaneous ( SC )&#xD;
      injection to patients with leukopenia in association with HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>Cytopenias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Serum antibody to HIV with or without evidence of HIV.&#xD;
&#xD;
          -  Antigenemia.&#xD;
&#xD;
          -  Anticipated survival of at least 6 months.&#xD;
&#xD;
          -  Allowed:&#xD;
&#xD;
          -  Kaposi's sarcoma.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Malignancy other than Kaposi's sarcoma.&#xD;
&#xD;
          -  Excessive diarrhea (more than 5 liquid or non-liquid stools per day).&#xD;
&#xD;
          -  Currently hospitalized or hospitalized within the last 4 weeks for the treatment of&#xD;
             opportunistic infection.&#xD;
&#xD;
          -  Primary hematologic or infectious disorders unrelated to AIDS virus infection.&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit the giving and understanding of&#xD;
             informed consent.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of malignancy other than Kaposi's sarcoma.&#xD;
&#xD;
          -  Currently hospitalized or hospitalized within 4 weeks for the treatment of&#xD;
             opportunistic infection.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 3 weeks of study entry:&#xD;
&#xD;
          -  Marrow suppressive medication.&#xD;
&#xD;
          -  Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Any investigational drug.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Systemic cytotoxic chemotherapy.&#xD;
&#xD;
          -  Irradiation.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded within 3 months of study entry:&#xD;
&#xD;
          -  Regular, excessive users of alcohol, hallucinogens, or agents which are addicting.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess - West Campus</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Leukopenia</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Leukopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

